RI

RIBOMIC Inc.

Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.

4591 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区白金台3−16−13 白金台ウスイビル6階
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

RIBOMIC Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of aptamer therapeutics. The company utilizes its proprietary RiboART system, a unique platform technology, to generate first-in-class, molecularly targeted drugs using RNA aptamers. RIBOMIC's research and development pipeline focuses on addressing unmet medical needs in a range of therapeutic areas, including ophthalmic disorders, pain, fibrosis, bone diseases, and rare diseases. The company pursues its mission through internal drug development programs and strategic partnerships within the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-23 08:45
Prospectus
有価証券届出書(組込方式)
Japanese 326.2 KB
2025-06-20 03:50
Regulatory News Service
確認書
Japanese 7.9 KB
2025-06-20 03:49
Regulatory News Service
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 22.3 KB
2025-06-20 03:43
Annual Report
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2024-11-13 02:14
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-11-13 02:13
Interim Report
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 207.6 KB
2024-06-26 04:47
Regulatory News Service
臨時報告書
Japanese 22.7 KB
2024-06-26 04:45
Regulatory News Service
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 22.1 KB
2024-06-26 04:44
Regulatory News Service
確認書
Japanese 8.0 KB
2024-06-26 04:43
Annual Report
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 2.0 MB
2024-02-14 02:26
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-02-14 02:25
Quarterly Report
四半期報告書-第21期第3四半期(2023/10/01-2023/12/31)
Japanese 178.6 KB
2023-11-13 08:01
Regulatory News Service
確認書
Japanese 7.9 KB
2023-11-13 08:01
Quarterly Report
四半期報告書-第21期第2四半期(2023/07/01-2023/09/30)
Japanese 203.1 KB
2023-08-10 08:46
Report Publication Announcement
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all RIBOMIC Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for RIBOMIC Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Hybrigenics SA Logo
R&D provider of molecular interaction analysis to accelerate drug discovery for life science sectors.
France ALHYG
Korean CRO offering end-to-end clinical trial services for pharma & bio ventures.
South Korea 187660
HYUNDAI BIOSCIENCE CO., LTD. Logo
Clinical-stage biotech developing safer antiviral & anticancer drugs via advanced drug delivery systems.
South Korea 048410
IMGT Corporation Limited Logo
Develops a drug delivery platform using ultrasound and nanotech for oncology.
South Korea 456570
Immunic AG Logo
Developing oral therapies for autoimmune diseases like multiple sclerosis and celiac disease.
United States of America IMUX
Operates one of Japan's largest ad networks and a 'Furusato Nozei' tax donation website.
Japan 6535
INBIOGEN CO.,Ltd Logo
Data mining, bioinformatics, and virtual assistance for the life sciences industry.
South Korea 101140
Incross Co.,Ltd. Logo
A digital marketing firm offering data-driven ad solutions via proprietary AI and video platforms.
South Korea 216050
INEST,Inc. Logo
Offers ASP solutions and HR support to businesses and sells mobile devices to consumers.
Japan 7111
Innate Pharma Logo
Clinical-stage biotech developing NK cell-engaging antibodies for cancer immunotherapy.
France IPH

Talk to a Data Expert

Have a question? We'll get back to you promptly.